

Docket No.: 2815-0374PUS1

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Dan PETERS et al.

Application No.: NEW

Confirmation No.: N/A

Filed: July 21, 2006

Art Unit: N/A

For:

DIMERIC AZACYCLIC COMPOUNDS AND Examiner: Not Yet Assigned

THEIR USE

## INFORMATION DISCLOSURE STATEMENT (IDS)

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

10/586838

Application No.: NEW

AP20 RECULUI/1021 JUL 2006

A concise explanation of relevance of some of the items listed on form PTO/SB/08 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references. Additionally, please note that WO-A1-085727 corresponds to EP-A1-1 282 620; and Brown et al., can be found cited in the specification.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: July 21, 2006

Respectfully submitted,

Gerald M. Murphy, Jr.

Registration No.: 28,977

BIRCH, STEWART, KOLASCH & BIRCH, LLP

8110 Gatehouse Road

Suite 100 East P.O. Box 747

Falls Church, Virginia 22040-0747

(703) 205-8000

Attorney for Applicant

## AP20 Rec'd PCT/P10 2 1 JUL 2006/08a/b (07-05) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Transport to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	NEWU / 586838	
				Filing Date	July 21, 2006	
				First Named Inventor	Dan PETERS	
				Art Unit	N/A	
				Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	2815-0374PUS1	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
		Number-Kind Code <sup>2</sup> ( if known)	AMA DD VOOC	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	

	FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages				
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	<sup>™</sup>			
	BA	WO-2004/076453-A1	09-10-2004						
	BB	WO-2004/039815-A1	05-13-2004						
	ВС	WO-02/04442-A1	01-17-2002						
	BD	EP-0 709 381-A1	05-01-1996						
	BE	EP-1 282 620-A1	02-12-2003						
	BF	WO-01/85727-A1	11-15-2001						

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>8</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	CA	CHRISTOPOULOS, et al., The Journal of Pharmacology and Experimental Therapeutics, vol. 298, no. 3, 2001, pages 1260-1268.		
	СВ	BROWN et al., Journal of Medicinal Chemistry. 1999, Vol. 42, No. 7, pages 1306-1311.		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.J./ (12/15/2008)

Examiner	/Noble Jarrell/ (12/15/2008)	Date	
Signature		Considered	·

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.